yahoo_financeOriginal article
Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell
Phase 1positiveSER-155Positive
AI Analysis
Summary
Seres Therapeutics announced that SER-155 met its primary endpoint in a Phase 1 trial, resulting in pre-market share price increases.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
Primary endpoint met
Importance:5/10
Sentiment:
0.80
clinical_trialphase_1positive_dataSER-155
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 11:55 AM